Breaking News Instant updates and real-time market news.

GILD

Gilead

10:31
04/04/16
04/04
10:31
04/04/16
10:31

Gilead deal a 'modest' positive now that could be significant later, says UBS

After Gilead announced a deal to acquire Nimbus Apollo and its Acetyl-CoA Carboxylase inhibitor program, UBS analyst Matthew Roden said he sees the acquisition as a "modest" positive for now that could become a significant positive later if the lead program for non-alcoholic steatohepatitis, or NASH, were to be successful. Roden thinks Nimbus' NDI-010976 could be used in sequential or combination therapy with Gilead's assets and he wouldn't be surprised if Gilead continues to add assets to its NASH portfolio. He keeps a Buy rating and $130 price target on Gilead shares.

  • 13

    Apr

  • 13

    May

  • 23

    May

  • 28

    Jun

GILD Gilead

03/15/16
JEFF
03/15/16
NO CHANGE
Target $97
JEFF
Hold
Gilead price target lowered to $97 on Zydelig trial stops at Jefferies
Jefferies analyst Brian Abrahams lowered his price target for Gilead Sciences to $97 from $100 after the company decided to stop six of its main Zydelig trials. The move likely caps any meaningful future growth for the cancer drug should it remain on the market, Abrahams tells investors in a research note. He expects the impact on Gilead to be "relatively minimal," however. The analyst keeps a Hold rating on the shares.
03/16/16
LEER
03/16/16
NO CHANGE
Target $127
LEER
Outperform
Gilead price target lowered to $127 on Zydelig at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Gilead Sciences to $127 from $130 after the company said it is discontinuing any program featuring Zydelig in a front-line setting. The analyst says his core thesis is unchanged and keeps an Outperform rating on Gilead.
03/23/16
RBCM
03/23/16
NO CHANGE
RBCM
Court decision won't have major impact on Gilead stock, says RBC Capital
After a jury ruled that Merck's (MRK) nucleotide patents are valid, RBC Capital says the ruling means that Gilead's (GILD) Sovaldi/Harvoni drug may be infringing on the patent, and that Gilead may have to pay financial damages including royalties to Merck. Nonetheless, RBC estimates that in a worst case scenario, Gilead's stock would only drop by about 5% as a result of these developments. The firm expects Gilead to appeal the ruling, and it notes that Merck is not seeking a ban on Gilead's infringing products. RBC keeps an Outperform rating on Gilead.
03/28/16
LEER
03/28/16
NO CHANGE
Target $127
LEER
Outperform
Leerink calls Merck's Zepatier 'another pretender' in HCV space
Leerink analyst Geoffrey Porges says Gilead's (GILD) Hepatitis C virus franchise is proving durable in the face of increased competition. In a research note titled "Another Pretender to HCV Throne Seems to Be Suffering the AbbVie Fate," Porges notes that seven weeks post the launch of Merck's (MRK) Zepatier, Gilead's Sovaldi and Harvoni "retain a relatively favorable position" in 65% of the top 20 largest commercial plans and 70% of the top 10 largest government plans relative to AbbVie's (ABBV) Viekira Pak and Zepatier. Script data and review of the largest payer plan formularies reveal that Gilead's HCV direct-acting antivirals are continuing to dominate the market, with modest share gains for rivals, the analyst writes. He believes Zepatier's early script trajectory is significantly lower than Viekira Pak's with no sign of an inflection or acceleration. The analyst reiterates an Outperform rating on Gilead Sciences with a $127 price target. The drugmaker closed Friday up $1.24 to $91.32.

TODAY'S FREE FLY STORIES

RHT

Red Hat

$173.28

-0.22 (-0.13%)

, IBM

IBM

$118.90

1.73 (1.48%)

12:41
11/21/18
11/21
12:41
11/21/18
12:41
Periodicals
EC review of Red Hat-IBM deal to 'zoom in' on middleware, Dealreporter says »

The European Commission…

RHT

Red Hat

$173.28

-0.22 (-0.13%)

IBM

IBM

$118.90

1.73 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

AAL

American Airlines

$36.91

1.31 (3.68%)

12:36
11/21/18
11/21
12:36
11/21/18
12:36
Periodicals
American Airlines glitch briefly hampers travelers, USA Today reports »

A computer glitch in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$48.54

0.22 (0.46%)

, FOXA

21st Century Fox

$48.84

0.25 (0.51%)

12:25
11/21/18
11/21
12:25
11/21/18
12:25
OnTheFly
Box Office Battle: 'Wreck-It Ralph' seen knocking out 'Beasts,' 'Creed' »

DISNEY EXPECTED TO WIN…

FOX

21st Century Fox

$48.54

0.22 (0.46%)

FOXA

21st Century Fox

$48.84

0.25 (0.51%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$37.34

0.59 (1.61%)

T

AT&T

$29.95

0.54 (1.84%)

DIS

Disney

$113.45

1.67 (1.49%)

VIA

Viacom

$35.28

1.06 (3.10%)

VIAB

Viacom

$31.82

1 (3.24%)

SNE

Sony

$50.75

1.21 (2.44%)

LGF.A

Lionsgate

$19.08

0.77 (4.21%)

LGF.B

Lionsgate

$17.64

0.78 (4.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 29

    Nov

  • 03

    Dec

  • 04

    Dec

AG

First Majestic

$5.52

0.28 (5.34%)

12:25
11/21/18
11/21
12:25
11/21/18
12:25
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/21/18
11/21
12:17
11/21/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/21/18
11/21
12:16
11/21/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.79

0.69 (0.39%)

, DE

Deere

$143.72

5.23 (3.78%)

12:15
11/21/18
11/21
12:15
11/21/18
12:15
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in positive…

AAPL

Apple

$177.79

0.69 (0.39%)

DE

Deere

$143.72

5.23 (3.78%)

GPS

Gap

$25.58

0.93 (3.77%)

FB

Facebook

$136.30

3.83 (2.89%)

TNDM

TNDM

BZUN

Baozun

$33.26

3.19 (10.61%)

FL

Foot Locker

$52.48

6.38 (13.84%)

JNJ

Johnson & Johnson

$142.00

-4.44 (-3.03%)

CAL

Caleres

$28.43

-2.5 (-8.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

  • 12

    Dec

  • 03

    Mar

NKTR

Nektar

$37.50

-0.7 (-1.83%)

12:05
11/21/18
11/21
12:05
11/21/18
12:05
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

HD

Home Depot

$170.35

1.18 (0.70%)

12:03
11/21/18
11/21
12:03
11/21/18
12:03
Hot Stocks
Home Depot director Mark Vadon purchases over $2M worth of company stock »

Home Depot director Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

, AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Recommendations
Dr. Reddy's, Aquestive Therapeutics analyst commentary  »

BMO says Aquestive loss…

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AET

Aetna

$205.78

1.635 (0.80%)

, CVS

CVS Health

$75.77

0.25 (0.33%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02
Hot Stocks
NJ state clears CVS-Aetna merger »

According to a filing,…

AET

Aetna

$205.78

1.635 (0.80%)

CVS

CVS Health

$75.77

0.25 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

12:01
11/21/18
11/21
12:01
11/21/18
12:01
General news
EIA natural gas storage change for week ending November 16 »

Gas inventories 134 Bcf…

GS

Goldman Sachs

$193.29

1.95 (1.02%)

11:55
11/21/18
11/21
11:55
11/21/18
11:55
Periodicals
Abu Dhabi fund sues Goldman Sachs over 1MDB scandal, FT says »

Abu Dhabi's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNHBF

ICC International Cannabis

$0.00

(0.00%)

, CGC

Canopy Growth

$34.08

2.17 (6.80%)

11:51
11/21/18
11/21
11:51
11/21/18
11:51
OnTheFly
Rising High: International Cannabis agrees to acquire Green Gene »

Welcome to "Rising High,"…

KNHBF

ICC International Cannabis

$0.00

(0.00%)

CGC

Canopy Growth

$34.08

2.17 (6.80%)

MMNFF

MedMen

$0.00

(0.00%)

ACB

Aurora Cannabis

$6.27

0.23 (3.81%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$8.57

0.38 (4.64%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$0.00

(0.00%)

TLRY

Tilray

$107.50

3.56 (3.43%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CRM

Salesforce

$124.33

3.61 (2.99%)

11:50
11/21/18
11/21
11:50
11/21/18
11:50
Options
Put spread in Salesforce as shares bounce 3% »

Put spread in Salesforce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Treasury's $11 B 10-year TIPS reopening was ok »

Treasury's $11 B…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Atlanta Fed's Q4 GDPNow estimate was unchanged at 2.5% »

Atlanta Fed's Q4…

11:45
11/21/18
11/21
11:45
11/21/18
11:45
General news
Breaking General news story  »

Week of 11/16 EIA Natural…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

, RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

11:44
11/21/18
11/21
11:44
11/21/18
11:44
Recommendations
Aquestive Therapeutics, Dr. Reddy's analyst commentary  »

Aquestive selloff on…

AQST

Aquestive Therapeutics

$9.60

-3.57 (-27.11%)

RDY

Dr. Reddy's

$36.89

0.41 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HIG

Hartford Financial

$44.70

0.6 (1.36%)

11:40
11/21/18
11/21
11:40
11/21/18
11:40
Options
Higher option volume in Hartford fueled by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

11:36
11/21/18
11/21
11:36
11/21/18
11:36
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

11:35
11/21/18
11/21
11:35
11/21/18
11:35
General news
Treasury announced a $111 B package of short dated coupons auctions for next week »

Treasury announced a $111…

BECN

Beacon Roofing

$32.97

4.9 (17.46%)

11:32
11/21/18
11/21
11:32
11/21/18
11:32
Upgrade
Beacon Roofing rating change  »

Beacon Roofing upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PCG

PG&E

$24.20

0.64 (2.72%)

11:30
11/21/18
11/21
11:30
11/21/18
11:30
Options
2K PG&E Mar 28 - 33 call spreads bought for $1.58 »

2K PG&E Mar 28 - 33…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.